用狂犬病毒核蛋白基因小干扰RNA库抑制狂犬病毒复制和感染的研究

采用RNaseⅢ消化长片段双链RNA的方法,制备了狂犬病毒N基因、P基因和G基因小干扰RNA库(siRNACocktail)。将siRNA转染BSR和MNA细胞单层后,采用直接免疫荧光法观察发现,N基因siRNACocktail能够对RV的复制和感染产生明显和稳定的抑制作用,并且通过RT-PCR在转录水平探测到mRNA产量的降低;而P基因或G基因siRNACocktail对RV的复制和感染不产生或仅产生弱的抑制作用。这一结果为RNA干扰在RV研究中靶基因的选择及进一步的应用提供了依据。     

载体表达的siRNA分子对猪圆环病毒2型复制的抑制作用

[目的]寻找一种基于RNA干扰技术的猪圆环病毒2型感染的防控方法.[方法]根据猪圆环病毒2型毒株基因组核苷酸序列,设计了3条特异性小干扰RNA(short interfering RNA,siRNA)分子,其中2条针对猪圆环病毒1型和2型复制酶基因(rep),1条针对猪圆环病毒2型核衣壳蛋白基因(cap),将合成的DNA片段退火形成双链,分别连接到RNAi-Ready pSIREN-RetroQ ZsGreen载体鼠源U6启动子下游,转化大肠杆菌得到阳性克隆,测序鉴定后分别命名为Retro-SH1,Retro-SH4,Retro-SH6.用上述质粒转染PCV2感染前、后的Dulac细胞及肌肉注射PCV2感染前、后的BALB/c小鼠,应用实时定量PCR试验评价其对病毒在细胞及小鼠体内复制的抑制作用,免疫组化法检测脾脏中病毒的存在.[结果]感染PCV2前或后转染500 ng Retro-SH1,Retro-SH4,Retro-SH6质粒能有效抑制PCV2在Dulac细胞上的复制,抑制率最高可达99%以上,对10株不同来源的临床分离株在细胞中复制的抑制作用同样明显,且不同毒株间差异不大.动物试验中,肌肉注射10μg上述不同siRNA分子对小鼠体内PCV2的复制有一定的抑制作用,其抑制率在26%至99%之间.[结论]载体表达的siRNA分子可能成为防控猪圆环病毒2型感染的一种新工具.     

鸡传染性支气管炎病毒的RNA干扰

为探讨短的双链RNA(siRNA)对鸡传染性支气管炎病毒(IBV)增殖的干扰作用,利用软件设计siRNA 1280个,75%位于Pol基因内.通过同源比较和保守性分析,筛选到针对Pol、M、N基因的12个siRNA(每个基因3～4个)作为后选目的片段,分别在Vero细胞、9日龄SPF鸡胚上进行基因干扰试验.结果,来自Pol、N靶序列的2个siRNA在Vero细胞上及鸡胚上均对IBV增殖产生明显的干扰作用,并与siRNA剂量有一定相关性,依赖于与mRNA互补的负链siRNA存在.本研究首次证实IBV增殖过程中存在siRNA干扰现象,为利用RNA干扰(RNAi)技术控制IBV提供了新手段.     

特异性干扰PB-1基因对H5N1高致病性禽流感病毒复制的影响

针对H5N1高致病性禽流感病毒PB-1基因,通过RNA干扰技术,设计siRNA,研究其抑制病毒复制的效果.siRNA转染MDCK细胞并接毒后,病毒滴度测定、Real-time PCR和间接免疫荧光试验结果显示,所设计的siRNA(ps-PB1-777)具有明显的抑制病毒复制的效果,PB-1基因的拷贝数和病毒蛋白表达都下降.设计的siRNA可显著抑制高致病性禽流感病毒的复制.因此,本研究中PB-1基因的有效siRNA可为预防和治疗H5N1高致病性禽流感提供合理的技术支持和物质储备.     

细胞水平狂犬病病毒感染的RNA干扰

以质粒pSilencer2.1-U6 Hygro为基础,设计并构建了针对狂犬病病毒(RV)糖蛋白和核蛋白mRNA的共9个siRNA表达载体,转染BHK-21细胞系后,在潮霉素-B的筛选压力下,获得9个稳定转录相关siRNA的BHK-21细胞株。1000TCID50的RV分别感染24孔板内的上述9株细胞,48h后以直接免疫荧光法检测各株细胞上RV的增殖,结果显示,在经不同siRNA表达载体转染的BHK-21细胞中,RV增殖水平有不同程度下降,RV增殖水平最低者为对照细胞的1%,即RNA干扰效应最高可阻断99%RV的感染。针对其中阻断水平超过90%的靶序列G69和N19,人工合成其双链siRNA,瞬时转染BHK-21细胞后,仍可达到80%以上的感染阻断率。本试验为有效阻断RV早期感染提供了新选择,为通过RNAi研究RV的基因组功能提供了新的依据。     

siRNA对SARS冠状病毒复制的抑制作用

为探讨siRNA在哺乳动物细胞中对SARS冠状病毒复制的抑制作用,针对BJ0 1株SARS冠状病毒复制酶基因(Pol)和刺突蛋白基因(S) ,设计4个siRNA ,并构建相应的siRNA表达载体及克隆细胞系.利用间接免疫荧光法及实时定量反转录PCR法,检测所设计的siRNA对SARS冠状病毒复制的抑制作用.结果表明,针对Pol基因的siRNA(psOe)在Vero细胞中可阻断BJ0 1株SARS病毒RNA的复制及其蛋白的表达.该结果为深入阐明SARS冠状病毒的致病机理及探讨SARS病毒防治新途径奠定了基础.     

小鼠体内SEG蛋白靶向运送shRNA抑制狂犬病毒复制

【目的】本试验前期已经证实,用单链抗体(sc Fv)-绿脓杆菌跨膜区(ETA)-酵母DNA结合结构域(GAL4)表达的蛋白(简写为SEG蛋白),SEG能与含sh RNA(short hairpin RNA)的质粒(p RNATU6.3-sh RNA)结合形成复合物SEG-sh RNA,并靶向运送该质粒进入感染狂犬病毒(Rabies virus,RV)的细胞,抑制RV复制。本研究用感染狂犬病病毒的小鼠模型,进行SEG-sh RNA复合物小鼠体内靶向性运送si RNA(short interfering RNA)和抑制RV复制的研究。【方法】用已建立RV CVS-24株小鼠肌肉注射模型进行试验。取50 LD_(50) CVS-24攻毒,在攻毒后12 h尾静脉注射SEG-sh RNA,流式细胞仪检测SEG-sh RNA的体内靶向性;同样方法攻毒后,尾静脉注射SEG-sh RNA,连续4 d,攻毒后第5天小鼠脑组织用q RT-PCR、RT-PCR、Western blot、免疫荧光染色法检测其中RV的含量;统计小鼠存活率;并检测小鼠体内IFN-α含量,从而分析SEG-sh RNA在体内的抗病毒作用。【结果】结果表明仅在RV攻毒小鼠的注射部位检测到绿色荧光蛋白(green fluorescent protein,GFP)的表达,未注射RV的腿部及脑、肝、脾、肾均无GFP表达,说明SEG-sh RNA可靶向RV感染细胞运送sh RNA。攻毒后第5天脑组织q RT-PCR结果表明靶向药物组比病毒对照减少4.88倍(3.9/0.8);RT-PCR、Western blot、免疫荧光染色试验结果表明使用SEG-sh RNA组病毒量明显少于病毒对照组;且攻毒后13 d,动物存活率达50%,而病毒对照100%死亡。检测小鼠体内IFN-α未见升高。【结论】以上试验表明SEG蛋白在小鼠体内靶向运送含sh RNA的质粒到感染组织细胞;对小鼠体内RV有明显抑制作用,因此可以用于狂犬病毒感染的特异辅助性救治研究。     

表达登革病毒prM基因小干扰RNA的Vero细胞系的建立

prM蛋白是登革病毒膜蛋白M的前体,膜蛋白M对病毒的组装与成熟有重要作用,针对prM基因设计的小干扰RNA（siRNA）可短期抑制登革病毒复制.为了达到长期抑制登革病毒的效果,本研究构建了插入prM siRNA序列的重组慢病毒,利用流式细胞术分选以及杀稻瘟霉素抗性,筛选出稳定表达prM siRNA的非洲绿猴肾细胞（Vero细胞）系.经逆转录PCR及测序验证siRNA序列表达正确. Vero细胞中prM siRNA的表达率约为976%.当受到登革病毒攻击时,表达prM siRNA的Vero细胞能够明显抑制登革病毒prM基因的表达,并抑制登革病毒在Vero细胞中的复制.建立的Vero细胞系可用于RNA干扰防治登革病毒感染的进一步应用研究.     

鸡传染性支气管炎病毒的RNA干扰

为探讨短的双链RNA(siRNA)对鸡传染性支气管炎病毒(IBV)增殖的干扰作用,利用软件设计siRNA1280个,75%位于Pol基因内。通过同源比较和保守性分析,筛选到针对Pol、M、N基因的12个siRNA(每个基因3～4个)作为后选目的片段,分别在Vero细胞、9日龄SPF鸡胚上进行基因干扰试验。结果,来自Pol、N靶序列的2个siRNA在Vero细胞上及鸡胚上均对IBV增殖产生明显的干扰作用,并与siRNA剂量有一定相关性,依赖于与mRNA互补的负链siRNA存在。本研究首次证实IBV增殖过程中存在siRNA干扰现象,为利用RNA干扰(RNAi)技术控制IBV提供了新手段。     

RNA干扰与抗病毒感染

RNA干扰(RNAi)是由小干扰RNA(siRNA)引发的生物细胞内同源基因的转录后基因沉默(PTGS)现象,是一种古老的生物抵抗外在感染的防御机制。RNAi因其在维持基因组稳定、调控基因表达和保护基因组免受外源核酸侵入等方面发挥的重要作用,已被广泛用于探索基因功能、基因治疗和新药的研发。外源导入siRNA引发的RNAi可以特异性抑制病毒的复制与感染,为抗病毒感染治疗开辟了一条新的途径。     

Hemagglutination by Rabies Virus

Goose erythrocytes were agglutinated by five strains of rabies virus grown in monolayer cell cultures at pH 6.4 and at 0 to 4 C. Hemagglutination was not affected by the cell type in which the virus was grown. Prerequisites for occurrence of hemagglutination are absence of hemagglutination inhibitors (such as those contained in bovine serum) and a relatively high virus concentration (> 10(6) plaque-forming units of virus per ml). "Soluble" hemagglutinin was not present in crude preparations of extracellular virus. Treatment of purified preparations of extracellular virus with Tween 80 and ether did not result in release of a "soluble" hemagglutinin. The hemagglutinating property of extracellular virus seemed to be conditioned by the integrity of its coat. Preparations of infectious intracellular virus exhibited about 15 times lower hemagglutinating activity than extracellular virus. This decreased hemagglutinating activity did not seem to be caused by binding of hemagglutination inhibitors to the virus particles. Rabies virus can be quantitatively adsorbed onto and eluted from erythrocytes. Erythrocytes pretreated with rabies virus retained their ability to be agglutinated by the same virus strain. The reaction with rabies virus of erythrocytes treated with the receptor-destroying enzyme or KIO(4) was the same as that of nontreated erythrocytes. The hemagglutinating component of rabies virus, therefore, does not exhibit neuraminidase activity. Treatment of extracellular virus by various agents indicated that the hemagglutinating component consists of protein or lipoprotein. Sulfhydryl groups present in the viral hemagglutinin are essential for hemagglutination.     

Parainfluenza Virus 5 Expressing the G Protein of Rabies Virus Protects Mice after Rabies Virus Infection

Rabies remains a major public health threat around the world. Once symptoms appear, there is no effective treatment to prevent death. In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glycoprotein (G) of rabies (PIV5-G) as a therapy for rabies virus infection: we have found that PIV5-G protected mice as late as 6 days after rabies virus infection. PIV5-G is a promising vaccine for prevention and treatment of rabies virus infection.     

Structural Proteins of Rabies Virus

Purified rabies virions, unlabeled or labeled with radioactive amino acids or d-glucosamine, were dissociated into their polypeptides by treatment with sodium dodecyl sulfate in a reducing environment and fractionated by electroiphoresis in sodium dodecyl sulfate-containing polyacrylamide gel. The molecular weights of individual polypeptides were estimated by comparison of their rate of migration with that of protein markers of known molecular weight. Purified viral nucleocapsid and a mixture of envelope components, isolated from virions disrupted by sodium deoxycholate, were analyzed by the same procedure. The number of molecules per virion of each polypeptide was estimated from the proportions of the separated components, the known molecular weight of the viral ribonucleic acid, and the chemical composition of the nucleocapsid. The protein moiety of the nucleocapsid particle was estimated to consist of 1,713 molecules of a major polypeptide (molecular weight, 62,000 daltons) and 76 molecules of a minor polypeptide (molecular weight, 55,000 daltons). In addition to 1,783 molecules of a glycoprotein component (molecular weight, 80,000 daltons), the viral envelope contains 789 and 1,661 molecules, respectively, of two other polypeptides (molecular weight, 40,000 and 25,000 daltons).     

A Novel Rabies Vaccine Based on a Recombinant Parainfluenza Virus 5 Expressing Rabies Virus Glycoprotein

Untreated rabies virus (RABV) infection leads to death. Vaccine and postexposure treatment have been effective in preventing RABV infection. However, due to cost, rabies vaccination and treatment have not been widely used in developing countries. There are 55,000 human death caused by rabies annually. An efficacious and cost-effective rabies vaccine is needed. Parainfluenza virus 5 (PIV5) is thought to contribute to kennel cough, and kennel cough vaccines containing live PIV5 have been used in dogs for many years. In this work, a PIV5-vectored rabies vaccine was tested in mice. A recombinant PIV5 encoding RABV glycoprotein (G) (rPIV5-RV-G) was administered to mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation. The vaccinated mice were challenged with a 50% lethal challenge dose (LD₅₀) of RABV challenge virus standard 24 (CVS-24) intracerebrally. A single dose of 10⁶ PFU of rPIV5-RV-G was sufficient for 100% protection when administered via the i.n. route. The mice vaccinated with a single dose of 10⁸ PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%). Intriguingly, the mice vaccinated orally with a single dose of 10⁸ PFU of rPIV5-RV-G showed a 50% survival rate, which is comparable to the 60% survival rate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE. This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate that rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines.     

Modular Organization of Rabies Virus Phosphoprotein

A phosphoprotein (P) is found in all viruses of the Mononegavirales order. These proteins form homo-oligomers, fulfil similar roles in the replication cycles of the various viruses, but differ in their length and oligomerization state. Sequence alignments reveal no sequence similarity among proteins from viruses belonging to the same family. Sequence analysis and experimental data show that phosphoproteins from viruses of the Paramyxoviridae contain structured domains alternating with intrinsically disordered regions. Here, we used predictions of disorder of secondary structure, and an analysis of sequence conservation to predict the domain organization of the phosphoprotein from Sendai virus, vesicular stomatitis virus (VSV) and rabies virus (RV P). We devised a new procedure for combining the results from multiple prediction methods and locating the boundaries between disordered regions and structured domains. To validate the proposed modular organization predicted for RV P and to confirm that the putative structured domains correspond to autonomous folding units, we used two-hybrid and biochemical approaches to characterize the properties of several fragments of RV P. We found that both central and C-terminal domains can fold in isolation, that the central domain is the oligomerization domain, and that the C-terminal domain binds to nucleocapsids. Our results suggest a conserved organization of P proteins in the Rhabdoviridae family in concatenated functional domains resembling that of the P proteins in the Paramyxoviridae family.     

狂犬病毒作为神经示踪剂的研究进展

狂犬病毒是仅有的完全特异的示踪剂,因为它能逆向通过化学突触进行神经示踪且不改变神经细胞的代谢,可以逐级的,时间依赖的方式感染大量的突触联系的神经网络.根据狂犬病毒的特性解释该病毒作为神经示踪剂的优势,总结狂犬病毒跨神经进行示踪的方法,并对基因修饰的狂犬病毒的新兴技术进行讨论和展望.     

用CaG株毒种制备精制狂犬病疫苗的研究

通过对狂犬病毒aG株在金黄地鼠肾细胞上传代培养,获得一种新型狂犬病毒毒株,即地鼠肾细胞适应株(CaG株)[1].由于该毒种具有生产方法简单,成本低廉,且外源因子污染机率小等优点,因此试用该毒种生产精制狂犬病疫苗.在相同条件下,分别用豚鼠脑毒种和细胞毒种各生产3批病毒原液,经相同纯化工艺制备成精制狂犬病疫苗.经初步检定用细胞毒种制备的疫苗安全性良好,疫苗免疫效价与豚鼠脑毒种疫苗无明显差异.